A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Cavosonstat (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms SNO-6
  • Sponsors Nivalis Therapeutics
  • Most Recent Events

    • 01 May 2017 According to a Nivalis Therapeutics media release, following disappointing results of two phase II trials (SNO-6 and SNO-7) of cavosonstat in cystic fibrosis, the company has determined to not pursue the development of this drug in cystic fibrosis and to wind down its research and development activities.
    • 28 Nov 2016 Status changed from active, no longer recruiting to completed, as per a Nivalis Therapeutics media release.
    • 28 Nov 2016 Top-line results published in a Nivalis Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top